Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics

Miro E. Raeber,Dominic P. Caspar,Yves Zurbuchen,Nannan Guo,Jonas Schmid,Jan Michler,Alina C. Martin,Urs C. Steiner,Andreas E. Moor,Frits Koning,Onur Boyman
DOI: https://doi.org/10.1016/j.immuni.2024.07.016
IF: 32.4
2024-09-11
Immunity
Abstract:Low doses of IL-2 can specifically activate regulatory T cells, making this an attractive therapeutic option for autoimmune diseases. Raeber et al. generated a comprehensive atlas of immune responses to low-dose IL-2 immunotherapy in systemic lupus erythematosus patients and identified distinct IL-2-driven regulatory T cell activation and tissue-homing programs.
immunology
What problem does this paper attempt to address?